Edition:
United States

Biotechnology & Medical Research

Celgene and LYSARC provide update on the phase III study

Celgene Corp : Interim analysis of overall survival, a key secondary endpoint, showed no benefit in revlimid . Based upon these interim results, Celgene does not currently plan to seek approval for this indication . Says is also exploring multiple clinical candidates in non-hodgkin lymphomas and...

4:30pm EDT

Gilead Sciences Q2 non-GAAP earnings per share $3.08

Gilead Sciences Inc : Q2 Harvoni sales $ 2.56 billion versus $3.61 billion last year . Revised full year 2016 guidance . Q2 Sovaldi sales $ 1.36 billion versus $1.29 billion last year . Sees Fy Diluted EPS Impact Of Acquisition-Related, restructuring, stock-based compensation expenses and other...

4:08pm EDT

Epirus Biopharmaceuticals entered settlement satisfaction amendment with Livzon Mabpharm

Epirus Biopharmaceuticals Inc : On July 15, co entered into a settlement satisfaction amendment with Livzon Mabpharm Inc - SEC filing . On July 25, co filed a voluntary petition for relief under provisions of Chapter 7 of title 11 of United States code . Assets of company will be liquidated and...

11:42am EDT

PTC Therapeutics provides regulatory update on Translarna

: Says no longer anticipates that chmp will issue its opinion regarding ema approval of translarna in mid-2016 . Says confirmatory phase 3 act cf trial of translarna is currently ongoing . Says there is substantial risk that results from translarna trial, expected in early 2017, will be required for...

10:45am EDT

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.

Analyst Research

Report Title Price
Provider : Thomson Reuters StreetEvents
$75.00
Provider : Thomson Reuters StreetEvents
$75.00
Provider : Edison Investment Research
$10.00
Provider : Thomson Reuters StreetEvents
$75.00
Provider : Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.